Janus Henderson Group PLC 89bio, Inc. Transaction History

Janus Henderson Group PLC

$182 Billion
Q2 2024

A detailed history of Janus Henderson Group PLC transactions in 89bio, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 13,276,110 shares of ETNB stock, worth $109 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

13,276,110

Previous 12,603,382 5.34%

Holding current value

$109 Million

Previous $147 Million 27.51%

% of portfolio

0.06%

Previous 0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $4.92 Million - $7.33 Million	672,728 Added 5.34%	13,276,110 $106 Million
Q1 2024 May 15, 2024	BUY	$8.13 - $13.77 $30 Million - $50.8 Million	3,688,241 Added 41.37%	12,603,382 $147 Million
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $32.5 Million - $78.3 Million	4,885,938 Added 121.26%	8,915,141 $99.6 Million
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $1.37 Million - $1.76 Million	-90,715 Reduced 2.2%	4,029,203 $62.2 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $5.29 Million - $8.24 Million	373,880 Added 9.98%	4,119,918 $78.1 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $28.6 Million - $46.2 Million	2,726,659 Added 267.48%	3,746,038 $57.1 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $1.28 Million - $2.95 Million	231,387 Added 29.36%	1,019,379 $13 Million
Q3 2022 Nov 14, 2022	SELL	$3.02 - $7.0 $2.72 Million - $6.32 Million	-902,148 Reduced 53.38%	787,992 $4.56 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $3.53 Million - $6.79 Million	1,690,140 New	1,690,140 $5.45 Million
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $1.4 Million - $1.7 Million	-60,650 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $1.48 Million - $2.35 Million	60,650 New	60,650 $1.56 Million

Others Institutions Holding ETNB

# of Institutions

157

Shares Held

107M

Call Options Held

65K

Put Options Held

1.2M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $382M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC 89bio, Inc. Transaction History